FDA Accepts NDA for Giredestrant in ER-Positive Early-Stage Breast Cancer

Pharmaceutical Executive·Jun 2

This story is reported by Pharmaceutical Executive. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer

CancerNetwork·Jun 3

2

FDA Accepts NDA for Roche’s Giredestrant in Early-Stage Breast Cancer

The Clinical Trial Vanguard·Jun 3

3

FDA accepts New Drug Application for Roche’s giredestrant

GlobeNewswire·Jun 2

4

FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer

Targeted Oncology·Jun 2

5

FDA Weighs Giredestrant as Adjuvant Therapy for Early Breast Cancer

Medical Professionals Reference·Jun 2

6

FDA Grants Priority Review to Roche's Early-Stage Breast Cancer NDA

Yahoo Finance·Jun 2

7

Weekly Rundown: Genentech's oral breast cancer drug gets priority FDA review

Drug Discovery News·Jun 5

8

FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting

Business Wire·Jun 2